Healius Limited

Healius is forecast to deliver extraordinary earnings growth of over 103% per annum, with EPS growth of 101.6% annually over the next three years. Analysts expect the company to turn profitable by FY2028, with earnings projected at AU$7 million, signaling a meaningful operational turnaround.

Despite long-term optimism, Healius is expected to remain loss-making through FY2026 and FY2027, with projected earnings of -AU$27 million and -AU$2 million respectively. The path to profitability is slow and fragile, and a return on equity of only 3.9% in three years reflects a structurally weak business recovery.

Analysts at Simply Wall St estimate Healius's fair value at AU$5.59, suggesting the stock may be undervalued by approximately 48% at current prices. This deep discount to intrinsic value could represent a compelling entry point for investors willing to wait for the operational recovery to materialize.

The Healius share price has fallen sharply — down 35% in a single month at one point — and technical analysis signals a further potential decline of up to 45.69% over the next three months. The stock's long-term moving average remains above its short-term average, reinforcing a general sell signal.

Healius's projected revenue growth of 3.5% per annum is steady and consistent, supported by underlying demand in the pathology and diagnostics sector. The global pathology laboratory market is on a strong growth trajectory, which could provide a favorable tailwind for Healius's core business segments.

Healius's forecast revenue growth of 3.5% per year significantly lags the broader Australian market's expected growth of approximately 6.1–6.2% annually. This below-market revenue expansion raises concerns about competitive positioning and whether Healius can capture sufficient market share to justify investor confidence.